ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst / Institutional Investors' Conference on February 14, 202312-02-2023
12-02-2023
Accumulate Zydus Lifesciences; target of Rs 480: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 480 in its research report dated February 06, 2023.08-02-2023
Buy Zydus Lifesciences; target of Rs 500: ICICI Direct
ICICI Direct is bullish on Zydus Lifesciences recommended buy rating on the stock with a target price of Rs 500 in its research report dated February 04, 2023.07-02-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Earnings Conference call held on February 2, 202306-02-2023
Zydus Lifesciences: Transdermal opportunity to unfold
The US and domestic formulation businesses help the pharma company to do well in Q306-02-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)06-02-2023
Zydus Lifesciences net profit rises 24.48% to Rs 622.9 cr in Dec quarter
Zydus Lifesciences Ltd on Friday reported a 24.48 per cent rise in consolidated net profit at Rs 622.9 crore for the third quarter ended December 31, 2022. The company had posted a consolidated net profit of Rs 500.4 crore in the same period last fiscal, Zydus Lifesciences Ltd said in a regulatory filing. Consolidated total revenue from operations during the quarter under review stood at Rs 4,362.3 crore, as against Rs 3,639.8 crore in the year-ago period, it added. Total expenses in the third quarter were higher at Rs 3,620.7 crore, as compared to Rs 3,096.3 crore in the corresponding period last fiscal. In the third quarter, its business in India comprising formulations as well as consumer wellness registered revenues of Rs 1,643.6 crore, up 13 per cent, while the US formulations business registered revenues of Rs 1,925 crore, up 29 per cent from the year-ago period, the company said. Emerging markets formulations business registered revenues of Rs 307.8 crore, up 15 per cent an03-02-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find attached herewith the newspaper cutting dated February 3, 2023 with regard to unaudited financial results of the Company for the quarter and nine months ended on December 31, 2022 published in the Financial Express English and Gujarati Editions.03-02-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst / Institutional Investors' Conference03-02-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of the Company's Investor Call on the unaudited financial results for the quarter and nine months ended on December 31, 202202-02-2023